Last reviewed · How we verify

Discontinuation of Azathioprin

University of Zurich · FDA-approved active Small molecule

Discontinuation of Azathioprin is a Small molecule drug developed by University of Zurich. It is currently FDA-approved for Study of immune reconstitution following azathioprine withdrawal in autoimmune or transplant patients.

Discontinuation of azathioprine involves the cessation of an immunosuppressive drug that inhibits purine synthesis, thereby reducing the suppression of T and B lymphocyte proliferation.

Discontinuation of azathioprine involves the cessation of an immunosuppressive drug that inhibits purine synthesis, thereby reducing the suppression of T and B lymphocyte proliferation. Used for Study of immune reconstitution following azathioprine withdrawal in autoimmune or transplant patients.

At a glance

Generic nameDiscontinuation of Azathioprin
SponsorUniversity of Zurich
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Azathioprine is a purine analog that suppresses immune cell proliferation by inhibiting inosine monophosphate dehydrogenase and other enzymes in the purine synthesis pathway. Upon discontinuation, immune function gradually recovers as the drug is eliminated and lymphocyte populations rebound. This is not a therapeutic agent itself but rather the withdrawal of an existing immunosuppressive therapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Discontinuation of Azathioprin

What is Discontinuation of Azathioprin?

Discontinuation of Azathioprin is a Small molecule drug developed by University of Zurich, indicated for Study of immune reconstitution following azathioprine withdrawal in autoimmune or transplant patients.

How does Discontinuation of Azathioprin work?

Discontinuation of azathioprine involves the cessation of an immunosuppressive drug that inhibits purine synthesis, thereby reducing the suppression of T and B lymphocyte proliferation.

What is Discontinuation of Azathioprin used for?

Discontinuation of Azathioprin is indicated for Study of immune reconstitution following azathioprine withdrawal in autoimmune or transplant patients.

Who makes Discontinuation of Azathioprin?

Discontinuation of Azathioprin is developed and marketed by University of Zurich (see full University of Zurich pipeline at /company/university-of-zurich).

What development phase is Discontinuation of Azathioprin in?

Discontinuation of Azathioprin is FDA-approved (marketed).

What are the side effects of Discontinuation of Azathioprin?

Common side effects of Discontinuation of Azathioprin include Disease flare or relapse of underlying autoimmune condition, Immune reconstitution inflammatory syndrome (in some contexts).

Related